China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

000999

Rank in Stocks #2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
Share Price
$3.74
Market Cap
$6.23B
Change (1 day)
-2.11%
Change (1 year)
-8.54%
Country
CN
Trade China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)

Category

Healthcare
Revenue for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Revenue in Jun 2026 TTM: $4.76B
According to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. latest financial reports the company's current revenue (TTM) is $4.76B. In 2024 the company made a revenue of $3.78B an increase over the revenue in the year 2023 that was $3.49B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. from 2001 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $4.76B 5.44%
2025 $4.52B 19.38%
2024 $3.78B 8.26%
2023 $3.49B 42.90%
2022 $2.45B 17.16%
2020 $2.09B -1.74%
2019 $2.12B 8.83%
2018 $1.95B 14.22%
2017 $1.71B 32.12%
2016 $1.29B 6.34%
2015 $1.22B 3.56%
2014 $1.17B -2.29%
2013 $1.20B 7.98%
2012 $1.11B 28.69%
2011 $865.22M 30.83%
2010 $661.34M -6.96%
2009 $710.79M 12.37%
2008 $632.54M 35.93%
2007 $465.35M 26.67%
2006 $367.39M -0.13%
2005 $367.88M 23.67%
2004 $297.46M -7.95%
2003 $323.17M 23.51%
2002 $261.66M 15.95%
2001 $225.66M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$23.54B 394.15%
DE
$23.73B 398.34%
DE
$29.24B 513.92%
JP
$5.85B 22.80%
CH
$6.34B 33.16%
IN